© 2002 by Oxford University Press
Journal of the National Cancer Institute, Vol. 94, No. 9, 690-697,
May 1, 2002
© 2002 Oxford University Press
ARTICLE |
Host Circadian Clock as a Control Point in Tumor Progression
Affiliations of authors: E. Filipski, X. Li, T. G. Granda, M.-C. Mormont, X. Liu, F. Lévi, Institut National de la Santé et de la Recherche Médicale (INSERM), Equipe Propre INSERM 0118 "Cancer chronotherapeutics" (Université Paris XI), Paul Brousse Hospital, Villejuif, France; V. M. King, Department of Anatomy, University of Cambridge, U.K.; B. Claustrat, Service Radiopharmacie et Radioanalyse, Hôpital Neurocardiologique, Lyon, France; M. H. Hastings, Laboratory of Molecular Biology, Medical Research Council, Cambridge, U.K.
Correspondence to: Francis Lévi, M.D., Ph.D., Institut National de la Santé et de la Recherche Médicale (INSERM) Equipe Propre INSERM 0118 "Cancer chronotherapeutics" (Université Paris XI), Paul Brousse Hospital, 94800 Villejuif, France (e-mail: chronbio{at}club-internet.fr).
 |
ABSTRACT |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background: The circadian timing system controlled by the suprachiasmatic nuclei (SCN) of the hypothalamus regulates daily rhythms of motor activity and adrenocortical secretion. An alteration in these rhythms is associated with poor survival of patients with metastatic colorectal or breast cancer. We developed a mouse model to investigate the consequences of severe circadian dysfunction upon tumor growth. Methods: The SCN of mice were destroyed by bilateral electrolytic lesions, and body activity and body temperature were recorded with a radio transmitter implanted into the peritoneal cavity. Plasma corticosterone levels and circulating lymphocyte counts were measured (n = 75 with SCN lesions, n = 64 sham-operated). Complete SCN destruction was ascertained postmortem. Mice were inoculated with implants of Glasgow osteosarcoma (n = 16 with SCN lesions, n = 12 sham-operated) or pancreatic adenocarcinoma (n = 13 with SCN lesions, n = 13 sham-operated) tumors to determine the effects of altered circadian rhythms on tumor progression. Time series for body temperature and rest–activity patterns were analyzed by spectral analysis and cosinor analysis. Parametric data were compared by the use of analysis of variance (ANOVA) and survival curves with the log-rank test. All statistical tests were two-sided. Results: The 24-hour rest–activity cycle was ablated and the daily rhythms of serum corticosterone level and lymphocyte count were markedly altered in 75 mice with complete SCN destruction as compared with 64 sham-operated mice (two-way ANOVA for corticosterone: sampling time effect P<.001, lesion effect P = .001, and time x lesion interaction P<.001; for lymphocytes P = .001, .002, and .002 respectively). Body temperature rhythm was suppressed in 60 of the 75 mice with SCN lesions (P<.001). Both types of tumors grew two to three times faster in mice with SCN lesions than in sham-operated mice (two-way ANOVA: P<.001 for lesion and for tumor effects; P = .21 for lesion x tumor effect interaction). Survival of mice with SCN lesions was statistically significantly shorter compared with that of sham-operated mice (log-rank P = .0062). Conclusions: Disruption of circadian rhythms in mice was associated with accelerated growth of malignant tumors of two types, suggesting that the host circadian clock may play an important role in endogenous control of tumor progression.
|
INTRODUCTION |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The delivery of anticancer agents at specific circadian stages was shown to concurrently improve tolerability and/or antitumor efficacy in several murine tumor models (1–5). The clinical relevance of this principle was demonstrated in multicenter randomized trials, as the tolerability of mucosae and that of sensory nerves were improved fivefold and twofold, respectively, with chronomodulated chemotherapy as compared with drug infusion at a constant rate. Moreover, the antitumor activity of the chronotherapy regimen also showed enhancement that was statistically significant (P<.003) (6,7). Nevertheless, approximately 30% of cancer patients with metastatic disease display rhythm alterations, a condition that could influence the disease outcome (8,9). Thus, we recently found that severe alterations in the rest–activity circadian rhythm predicted a fivefold increase in the risk of death in patients with metastatic colorectal cancers as compared with those with normal rest–activity patterns (10). Similarly, an abnormal cortisol rhythm predicted a doubling of the risk of death in patients with metastatic breast cancer as compared with those with a normal cortisol pattern (11). Most importantly, the predictive value of alterations in these rhythms predicting poor survival outcome was independent from all known clinical factors in both studies.
Mammalian circadian rhythms are generated by interconnected molecular loops involving specific genes controlling the circadian clock [reviewed in (12)]. A central pacemaker consisting of suprachiasmatic nuclei (SCN), located in the hypothalamus, coordinates these rhythms and directly controls the rest–activity circadian cycle (13). The ablation of SCN results in the suppression of these rhythms in several rodent species, whereas transplantation of SCN restores these rhythms in animals with prior SCN lesions (14). The SCN are responsible for the adjustment of the whole circadian time structure to the photoperiodic environment, the main synchronizer of bodily rhythms (14). As a result, most biochemical or molecular cell processes display predictable changes along the 24-hour time scale, which can modulate anticancer drug pharmacology (15).
We hypothesized that severe circadian dysfunction could accelerate tumor progression per se and tested this possibility in mice with ablation of SCN before tumor inoculation.
|
METHODS |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Study Design
In a first series of experiments, we studied the effect of SCN destruction on the rhythms in rest–activity body temperature, plasma corticosterone concentration, and circulating lymphocyte count in 188 B6D2F1 mice. Mice were randomly allocated to receive sham operation (64 animals) or SCN lesions (124 animals). Fourteen mice from the latter group were eliminated from the study as a consequence of postoperative death or obesity resulting from the destruction of other hypothalamic nuclei. In a second study, B6D2F1 mice were randomly assigned to receive either sham operation (25 animals) or introduction of SCN lesions [45 animals before receiving a fragment of either Glasgow osteosarcoma (GOS) (16) or the more slowly growing pancreatic adenocarcinoma (P03) (17)]. Two mice with SCN lesions were monitored as non-tumor-bearing controls, and 14 mice were eliminated from the study because of postoperative death or obesity. Both tumor cell lines are known to display a circadian rhythm-modulated susceptibility to chemotherapy (18,19). Male B6D2F1 mice, 5–6 weeks old, were purchased from Charles River (L'Arbresle, France). All the experiments were performed in mice synchronized to 12 hours of light and 12 hours of darkness (LD 12 : 12, with lights on from 6:00 AM to 6:00 PM) to allow for an SCN-independent photoperiodic synchronization, which may be the case in clinically relevant situations. All procedures were performed in accordance with French guidelines for experimental animal care.
Monitoring Rhythms
Locomotor activity and body temperature were measured every 10 minutes throughout each experiment with the use of a radio transmitter (Physio Tel, TA 10 TA-F20; Data Sciences, St. Paul, MN) implanted into the peritoneal cavity of each mouse.
SCN Destruction and Fourier Analysis
The SCN were destroyed by bilateral electrolytic lesion (20) (1 mA for 4 seconds; stereotaxic coordinates: approximately [anterior/posterior] on the Bregma line, mediolateral [± 0.2 mm of midline], dorsoventral [0.55 mm below dural surface], incisor bar at the same level as the ear bars). Sham-operated animals underwent the same stereotaxic procedure without electrolytic lesions. Effective SCN lesions were identified by the loss of any dominant periodicity (
) of locomotor activity in the circadian domain (20 h < < 28 h) with Fourier transform spectral analysis following visual inspection (21). Complete SCN destruction was ascertained postmortem in all mice for pathologic changes by investigators who had no knowledge of any data on these mice with respect to rest–activity cycles, temperature patterns, or blood variables. Histologic methods involved both Nissl stain of the hypothalamus tissue and immunostaining for peptide histidine–isoleucine (PHI) (20,22,23).
Anesthesia
Mice were anesthetized with a single intraperitoneal injection of a 0.5-mL solution of 10 g of 2,2,2-tribromoethanol (Fluka, Saint-Quentin-Fallavier, France) in 10 mL of 2-methyl-2-butanol (Fluka) diluted 1 : 39 in 0.9% NaCl.
Assessment of Corticosterone Levels and Lymphocyte Counts
Blood samples were taken from separate groups of either animals with SCN lesions or sham-operated animals at one of six different times, 4 hours apart, over a 24-hour span (3, 7, 11, 15, 19, or 23 hours after light onset [HALO]), 3–7 weeks after introducing SCN lesions. Lymphocyte count was determined with a Cell DyneTM 3500R (Abbott Diagnostics, Rungis, France), and corticosterone concentration was measured by radioimmunoassay (RIA) (5 µL of plasma was extracted with 3 mL of diethyl ether; the residue was dissolved in 100 µL of assay buffer before incubation with 1,2,6,7 [3H]corticosterone [Amersham, Orsay, France] and rabbit anti-corticosterone antibody [Valbiotech, Paris, France]).
Tumor Models
GOS and P03 tumor cells were provided by the Research Center of Aventis Pharma (Vitry sur Seine, France). Both tumors were maintained in C57BL/6 female mice and passaged every 2 weeks (for GOS) or every 4 weeks (for P03) as bilateral subcutaneous implants. Three passages were required before tumor transplantation in the experimental mice. Tumor fragments of size 4 x 4 mm2 were prepared from dissected tumors grown in the donor mice and kept in Hanks' medium for approximately 1 hour. They were freshly implanted subcutaneously in each flank of male B6D2F1 mice with a 12-gauge trocar. The experiment followed a 2 x 2 factorial design to test the role of SCN lesions, that of tumor type, and an interaction term, with regard to tumor growth and survival.
Tumor size was measured three times a week using a caliper. Tumor weight (mg) was estimated from two perpendicular measurements (mm): tumor weight = (length x width2)/2.
Mice with tumor weight reaching approximately 2 g were sacrificed for ethical reasons and considered as dead from tumor progression on this date. Four mice (two with SCN lesions and two sham-operated) were not inoculated with tumor and served as healthy controls.
Statistical Analysis
Means and 95% confidence intervals were computed for each set of parameters. Intergroup differences were evaluated statistically using multiple-way analyses of variance (ANOVA). The effect of SCN lesions on tumor growth was assessed with 2-way ANOVA for repeated measures and followed by Student's t test. Time series were analyzed by spectral analysis (Fourier transform analysis) using Mathcad 6.0. Statistical significance of circadian rhythmicity was further documented by cosinor analysis (24). This method characterized a rhythm by the parameters of the fitted cosine function best approximating all data. A period = 24 hours was determined a priori. The rhythm characteristics estimated by this linear least squares method include the mesor (M, rhythm-adjusted mean), the double amplitude (2A, difference between minimum and maximum of fitted cosine function), and the acrophase (Ø, time of maximum in fitted cosine function, with light onset as Ø reference, so that units were in HALO). A rhythm was detected if the null hypothesis was rejected with P<.05; however, A and Ø were considered as valid imputations if .05<P<.10, as the statistical power could possibly be affected by the number of mice studied. Survival was computed with the Kaplan–Meier method, and differences in survival were validated with the log-rank test. All statistical tests were two-sided. All standard statistical tests were performed using SPSS for Windows software (Statistical Package for Social Sciences, Chicago, IL).
|
RESULTS |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Disruption of Circadian Coordination
The rest–activity cycle and the temperature rhythms of all sham-operated mice were marked and were found to be regular from one day to the next (a representative example is given in Fig. 1
, A, left panel, top and bottom, respectively). Spectral analysis adjusted best-fitting sinusoidal functions with decreasing periods to the data. The initial period (fundamental T) corresponded to the whole length of the time series (168 h in the examples shown in Fig. 1). The subsequent harmonic periods tested were T/2, T/3, T/4.....T/50. The 7th harmonic (T/7) corresponded to a period of 24 h. Thus, this method identified the 24-h period as the most prominent one among the initial 50 harmonics tested with corresponding periods ranging from 168 to 3.36 hours (Fig. 1, A, right panel, top and bottom). The rest–activity cycle was suppressed in 79 of 110 mice with SCN lesions (a representative example is given in Fig. 1, B, top left panel). Spectral analysis did not reveal any 24-hour periodicity that stood out among the initial 50 harmonics (Fig. 1, B, top right panel). A postmortem histologic study ascertained complete SCN destruction in 75 animals. Only the animals with histologically verified SCN destruction were included in the SCN lesion group for comparison. None of the sham-operated mice were excluded from the analysis. Body temperature rhythm was suppressed in 60 of the 75 mice with histologically verified SCN lesions (Fig. 1, B, lower left and right panels). An atypical body temperature rhythm was found in 15 of these 75 mice. It was confirmed by a dominant 24-hour periodicity with Fourier transform analysis and a statistically significant 24-hour rhythm with cosinor analysis (P<.001). The amplitude of temperature, however, was greatly decreased as compared with that of sham-operated mice; the maximum (acrophase) occurred between mid-light and early dark as compared with mid-dark in sham-operated animals (data not shown).
|
indicates the 12-hour light span and 
indicates the 12-hour dark span on the x-axis. For the spectral analysis (right panels), each vertical bar indicates the amplitude (ordinate) of the harmonic corresponding to the period tested (abscissa). In these examples, the fundamental period is 168 hours (duration of time series). The 7th harmonic corresponds to a period of 24 hours (168/7), and the 50th harmonic corresponds to a period of 3.37 hours (168/50).The corticosterone rhythm was similar in sham-operated mice and in control (unoperated) mice, with a peak located at the light–dark transition. The mean value at peak was roughly sevenfold greater than the mean trough value. The rhythm was altered in mice with lesions, with a mean peak value that was roughly twofold greater than the mean trough value. Furthermore, the peak was advanced to mid-light (Fig. 2, A
). Two-way ANOVA validated statistically significant effects of SCN lesion (P = .001), sampling time (P<.001), and lesion x time interaction (P<.001). According to cosinor analysis, 24-hour mean value was decreased from 28.5 ng/mL (in sham-operated mice) to 20.8 ng/mL (in mice with SCN lesions), and the circadian amplitude was reduced from 23.4 to 6.3 ng/mL (Table 1). The mean lymphocyte count of sham-operated mice reached maximum values in late dark to mid-light, twice as high as that of nadir in early dark. The rhythm was damped in mice with SCN lesions, with a mean value at peak (at late dark) exceeding by roughly 50% the mean value at trough (at late light) (Fig. 2, B). Two-way ANOVA demonstrated statistically significant effects of SCN lesion (P = .002), sampling time (P = .001), and lesion x time interaction (P = .002).
|
|
The severe damping of amplitude and the phase displacement in mice with SCN lesions were further validated with cosinor analysis (Table 1
). The mesor (approximately 24-h mean value) and the amplitude (approximately half of the circadian variability above or below the mesor) were statistically significantly reduced in mice with SCN lesions for both variables. The acrophase (timing of maximum, with light onset as phase reference) of plasma corticosterone and that of lymphocyte count, respectively, occurred 90 and approximately 420 minutes earlier in animals with SCN lesions as compared with those in sham-operated mice. Cosinor analysis confirmed the marked alterations that SCN lesions produced in circadian rhythms in peripheral blood. Relevance of Circadian Coordination for Tumor Growth
Twenty-nine mice with histologically confirmed SCN lesions had received either GOS (n = 16) or P03 (n = 13) tumors. Sham-operated animals had been transplanted with GOS (n = 12) or P03 (n = 13) tumors. The results indicated a highly statistically significant effect of SCN lesions and tumor type on tumor size (2-way ANOVA, P<.001 for lesion and for tumor effects), without any statistically significant interaction (lesion x tumor) (P = .21). Accelerated growth of each tumor in mice with SCN lesions was further statistically validated with one-way ANOVA (GOS, P = .004; P03, P<.001). In GOS tumor-bearing mice, tumor growth rate was faster in mice with SCN lesions than in sham-operated mice. On day 12, i.e., before the death of the first animal, mean tumor weight was 1443 mg (95% confidence interval [CI] = 1009 mg to 1844 mg) versus 490 mg (95% CI = 273 mg to 707 mg) in mice with SCN lesions and in sham-operated mice, respectively (for t test, P = .002) (Fig. 3, A). In mice bearing the slower growing P03 tumors, tumor growth rate was faster in mice with SCN lesions as compared with that in the sham-operated mice. On day 22, i.e., before the death of the first animal, mean tumor weights were 1447 mg (95% CI = 695 mg to 2199 mg) in mice with SCN lesions and 749 mg (95% CI = 458 mg to 1040 mg) in sham-operated mice (for t test, P = .05) (Fig. 3, B). Similarly, the survival of sham-operated mice was statistically significantly longer than that of mice with SCN lesions (median survival time in days: sham-operated mice = 26 (95% CI = 23 to 29); mice with SCN lesions = 22 (95% CI = 19 to 25); P for log-rank test = .0062). As we have observed in our previous studies, the mice with histologically verified partial SCN lesions (n = 4) displayed a normal circadian pattern in rest–activity and body temperature. Tumor growth rate in these mice was similar with that in control mice (data not shown).
|
|
DISCUSSION |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
This study demonstrates for the first time the functional role of SCN with regard to tumor growth. The SCN have long been regarded as the master circadian clock in view of their role in the rest–activity cycle (14). Nevertheless, their effect on other rhythms is less well established. Here, we 1) confirmed that SCN destruction ablated the rest–activity cycle in all the mice and 2) documented weak circadian coordination of several other rhythms. A persistent yet atypical body temperature rhythm was statistically validated in 20% of the mice. The amplitude was damped, and the maximum temperature occurred during the light span rather than during darkness, as was previously observed for this and other rodent species (25,26). A significant circadian variation was also found for plasma corticosterone and circulating lymphocyte count in the group of mice with SCN lesions. Both rhythms, however, displayed reduced amplitude and altered phase as compared with those in sham-operated mice. Two hypotheses could account for the occurrence of circadian rhythms despite SCN destruction. Either the light/dark cycle may be partly driving the abnormally phased rhythms in temperature, corticosterone, and lymphocyte count, although it had no overt effect on activity, or peripheral circadian oscillators may be able to function in the absence of the central clock control of the SCN, yet with poor synchrony (27). Indeed, functional circadian oscillators have been demonstrated recently in cultured mammalian cells and peripheral tissues (28–30).
SCN ablation accelerated malignant growth by twofold to threefold for two established tumors with different proliferation rates. In addition, tumor growth in the mice with partial SCN destruction was similar to that in controls, illustrating the need for complete SCN destruction to accelerate tumor proliferation. This remote antitumor effect of SCN may be mediated by either endocrine or neuroanatomic communications between the SCN and peripheral targets. For example, the existence of paracrine secretions from the SCN has been demonstrated by neural grafting experiments in which encapsulated SCN tissue can restore circadian patterning to locomotor activity in hosts with lesions (31). Additionally, the SCN have widespread anatomic associations with the autonomic nervous system (32), which may influence host responses and/or factors in the host environment that regulate tumor growth. Both tumor models have displayed sensitivity to immunotherapeutic agents (16,33), which suggests that SCN destruction could favor tumor progression through immune suppression. The mean lymphopenia that we observed in mice with SCN lesions was associated with a reduced mean serum corticosterone level, a finding divergent from what was expected, because lymphopenia usually results from glucocorticoid supplementation (34). This and the differential phase-shifting and amplitude-reduction effects of SCN destruction on serum corticosterone and lymphocyte count rhythms support distinct SCN control pathways of immunologic and adrenal rhythmic functions (35,36). Recent studies (30) highlight a role for corticosteroids in coordinating peripheral circadian oscillators located in a variety of tissues. The loss of temporal organization across tissues arising from SCN lesion-induced corticosteroid dysrhythmia may contribute to enhanced tumor growth. It is necessary to investigate further whether the endocrine or immune effects triggered by SCN lesions could differently affect transplanted or endogenous tumors. Yet, chemically induced carcinomas in rats were promoted by nonspecific methods of circadian alterations, such as continuous light exposure (37).
The current findings show that release from circadian regulation causes a dramatic acceleration of malignant growth, a result in line with recent clinical reports. In a study involving 200 patients with metastatic colorectal cancer, survival at 4 years was 22% in the patients with a marked rest–activity cycle as compared with 11% in those with damped or altered rhythm. As indicated by multivariate analysis, the prognostic value of circadian rhythmicity in rest–activity was independent of well-known prognostic factors such as performance status, number of organs with metastasis, or degree of liver tissue replacement by tumor (10). The relationship between salivary cortisol rhythm and survival was explored in 104 patients with previously treated metastatic breast cancer. A normal cortisol pattern, with peak concentration at 8:00 AM and decline thereafter, was found in 37% of the patients. This group had a 4-year survival rate of 55% as compared with 26% in the patients with an altered cortisol secretion pattern. Cortisol slope was an indepen-dent predictor of survival, as determined by the multivariate analysis (11). Two large epidemiologic studies (38–41) further showed that disrupted circadian coordination induced by light at night increased the risk of developing breast cancer in women. Although the clinical data support the idea that circadian clock function partly controls several stages of tumor development, our experimental model clearly demonstrates a specific role for the hypothalamic clock with regard to cancer proliferation.
We expect that improved understanding of the biologic dynamics of neoplasia will stem from an examination of the temporal interplay between the central SCN clock, peripheral tissue-based oscillators, and malignant processes and will lead to novel therapeutic approaches to cancer.
|
NOTES |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Supported in part by Association pour la Recherche sur le Cancer (ARC), Association pour la Recherche sur le Temps Biologique et la Chronothérapeutique (ARTBC), Institut de Cancer et d'Immunogénétique (ICIG; Villejuif, France), and by a Research Training Fellowship from Medical Research Council (to V. M. King).
E. Filipski, V. M. King, M. H. Hastings, and F. Lévi were involved in the conception of the study, study design, data acquisition, article drafting, revising, and final approval of the submitted version. XM. Li, T. G. Granda, M.-C. Mormont, XH. Liu, and B. Claustrat contributed to the study design, data acquisition, critical article revising, and approval of the final version.
|
REFERENCES |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1
Haus E, Halberg F, Pauly JE, Cardoso S, Kuhl JF, Sothern RB, et al. Increased tolerance of leukemic mice to arabinosyl cytosine with schedule adjusted to circadian system. Science 1972;177:80–2.
2
Ohdo S, Makinosumi T, Ishizaki T, Yukawa E, Higuchi S, Nakano S, et al. Cell cycle-dependent chronotoxicity of irinotecan hydrochloride in mice. J Pharmacol Exp Ther 1997;283:1383–8.
3
Filipski E, Amat S, Lemaigre G, Vincenti M, Breillout F, Levi F. Relationship between circadian rhythm of vinorelbine toxicity and efficacy in P388-bearing mice. J Pharmacol Exp Ther 1999;289:231–5.
4
Granda TG, Filipski E, D'Attino RM, Vrignaud P, Anjo A, Bissery MC, et al. Experimental chronotherapy of mouse mammary adenocarcinoma MA13/C with docetaxel and doxorubicin as single agents and in combination. Cancer Res 2001;61:1996–2001.
5 Levi F. Chronopharmacology of anticancer agents. In: Redfern PH, Lemmer B, editors. Handbook of experimental pharmacology. Vol 125. Physiology and pharmacology of biological rhythms. Chapter 11: Cancer chemotherapy. Berlin (Germany): Springer-Verlag; 1997. p. 299–331.
6 Levi F, Zidani R, Misset JL. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. International Organization for Cancer Chronotherapy. Lancet 1997;350:681–6.[CrossRef][Web of Science][Medline]
7 Levi F. Circadian chronotherapy for human cancers. Lancet Oncology 2001;2:307–15.[CrossRef][Medline]
8 Touitou Y, Bogdan A, Levi F, Benavides M, Auzeby A. Disruption of the circadian patterns of serum cortisol in breast and ovarian cancer patients: relationships with tumour marker antigens. Br J Cancer 1996;74:1248–52.[Web of Science][Medline]
9 Mormont MC, Levi F. Circadian system alterations during cancer processes: a review. Int J Cancer 1997;70:241–7.[CrossRef][Web of Science][Medline]
10
Mormont MC, Waterhouse J, Bleuzen P, Giacchetti S, Jami A, Bogdan A, et al. Marked 24-h rest/activity rhythms are associated with better quality of life, better response, and longer survival in patients with metastatic colorectal cancer and good performance status. Clin Cancer Res 2000;6:3038–45.
11
Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst 2000;92:994–1000.
12 Lowrey PL, Takahashi JS. Genetics of the mammalian circadian system: Photic entrainment, circadian pacemaker mechanisms, and posttranslational regulation. Annu Rev Genet 2000;34:533–62.[CrossRef][Web of Science][Medline]
13
Rusak B, Zucker I. Neural regulation of circadian rhythms. Physiol Rev 1979;59:449–526.
14 Klein DC, Moore RY, Reppert SM, editors. The suprachiasmatic nucleus: the mind's clock. New York (NY): Oxford University Press; 1991.
15 Redfern PH, Lemmer B, editors. Handbook of experimental pharmacology. Vol 125. Physiology and pharmacology of biological rhythms. Berlin (Germany): Springer-Verlag; 1997.
16 Glasgow LA, Crane JL Jr, Kern ER. Antitumor activity of interferon against murine osteogenic sarcoma cells in vitro. J Natl Cancer Inst 1978;60:659–66.[Web of Science][Medline]
17
Corbett TH, Roberts BJ, Leopold WR, Peckham JC, Wilkoff LJ, Griswold DP Jr, et al. Induction and chemotherapeutic response of two transplantable ductal adenocarcinomas of the pancreas in C57BL6 mice. Cancer Res 1984;44:717–26.
18
Tampellini M, Filipski E, Liu XH, Lemaigre G, Li XM, Vrignaud P, et al. Docetaxel chronopharmacology in mice. Cancer Res 1998;58:3896–904.
19 D'Attino RM, Filipski E, Granda TG, Vrignaud P, Bissery MC, Marceau-Suissa J, et al. Irinotecan (CPT-11) and oxaliplatin (l-OHP) synergistic activity at specific circadian times in tumor-bearing mice. Proceedings of the 91st Annual Meeting of the American Association of Cancer Research; 2000 April 1–5; San Francisco (CA). Linthicum (MD): Cadmus Journal Services; 2000. Abstract 1268.
20 Maywood ES, Smith E, Hall SJ, Hastings MH. A thalamic contribution to arousal-induced, non-photic entrainment of the circadian clock of the Syrian hamster. Eur J Neurosci 1997;9:1739–47.[CrossRef][Web of Science][Medline]
21 De Prins J, Hequet B. In: Touitou Y, Haus E, editors. Biologic rhythms in clinical and laboratory medicine. Berlin (Germany): Springer-Verlag; 1992. p. 90–113.
22 Mikkelsen JD, Larsen PJ, Sorensen GG, Woldbye D, Bolwig TG, Hastings MH, et al. A dual-immunocytochemical method to localize c-fos protein in specific neurons based on their content of neuropeptides and connectivity. Histochemistry 1994;101:245–51.[CrossRef][Web of Science][Medline]
23 Hastings MH, Best JD, Ebling FJP, Maywood ES, McNulty S, Schurov I, et al. Entraiment of the circadian clock. Brain research III Hypothalamic integration of circadian rhythms. In Buijs RM, Kalsbeek A, Romijn HJ, Pennartz CMA, Mirmiran M, editors. Progress in brain research. Vol 111. Amsterdam (The Netherlands): Elsevier Science BV; 1996. p. 147–54.
24 Nelson W, Tong Y, Lee JK, Halberg F. Methods for cosinor rhythmometry. Chronobiologia 1979;6:305–23.[Web of Science][Medline]
25
Li XM, Liu XH, Filipski E, Metzger G, Delagrange P, Jeanniot JP, et al. Relationship of atypical melatonin rhythm with two circadian clock outputs in B6D2F(1) mice. Am J Physiol Regul Integr Comp Physiol 2000;278:R924–30.
26 Benstaali C, Mailloux A, Bogdan A, Auzeby A, Touitou Y. Circadian rhythms of body temperature and motor activity in rodents and their relationships with the light-dark cycle. Life Sci 2001;68:2645–56.[CrossRef][Web of Science][Medline]
27
Stokkan KA, Yamazaki S, Tei H, Sakaki Y, Menaker M. Entrainment of the circadian clock in the liver by feeding. Science 2001;291:490–3.
28 Tosini G, Menaker M. Circadian rhythms in cultured mammalian retina. Science 1996;272:419–21.[Abstract]
29 Balsalobre A, Damiola F, Schibler U. A serum shock induces circadian gene expression in mammalian tissue culture cells. Cell 1998;93: 929–37.[CrossRef][Web of Science][Medline]
30
Balsalobre A, Brown SA, Marcacci L, Tronche F, Kellendonk C, Reichardt HM, et al. Resetting of circadian time in peripheral tissues by glucocorticoid signaling. Science 2000;289:2344–7.
31 Silver R, LeSauter J, Tresco PA, Lehman MN. A diffusible coupling signal from the transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. Nature 1996;382:810–3.[CrossRef][Medline]
32 Ueyama T, Krout KE, Nguyen XV, Karpitskiy V, Kollert A, Mettenleiter TC, et al. Suprachiasmatic nucleus: a central autonomic clock. Nat Neurosci 1999;2:1051–3.[CrossRef][Web of Science][Medline]
33 Damia G, Tagliabue G, Allavena P, D'Incalci M. Flavone acetic acid antitumor activity against a mouse pancreatic adenocarcinoma is mediated by natural killer cells. Cancer Immunol Immunother 1990;32:241–4.[CrossRef][Web of Science][Medline]
34 Dhabhar FS, Miller AH, McEwen BS, Spencer RL. Effects of stress on immune cell distribution. Dynamics and hormonal mechanisms. J Immunol 1995;154:5511–27.[Abstract]
35 Levi FA, Canon C, Touitou Y, Sulon J, Mechkouri M, Ponsart ED, et al. Circadian rhythms in circulating T lymphocyte subtypes and plasma testosterone, total and free cortisol in five healthy men. Clin Exp Immunol 1988;71:329–35.[Web of Science][Medline]
36
Depres-Brummer P, Bourin P, Pages N, Metzger G, Levi F. Persistent T lymphocyte rhythms despite suppressed circadian clock outputs in rats. Am J Physiol 1997;273:R1891–9.
37 van den Heiligenberg S, Depres-Brummer P, Barbason H, Claustrat B, Reynes M, Levi F. The tumor promoting effect of constant light exposure on diethylnitrosamine-induced hepatocarcinogenesis in rats. Life Sci 1999;64:2523–34.[CrossRef][Web of Science][Medline]
38 Stevens RG, Rea MS. Light in the built environment: potential role of circadian disruption in endocrine disruption and breast cancer. Cancer Causes Control 2001;12:279–87.[CrossRef][Web of Science][Medline]
39
Hansen J. Light at night, shiftwork, and breast cancer risk. J Natl Cancer Inst 2001;93:1513–5.
40
Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93:1557–62.
41
Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Rotating night shifts and risk of breast cancer in women participating in the nurses' health study. J Natl Cancer Inst 2001;93:1563–8.
Manuscript received July 9, 2001; revised February 5, 2002; accepted February 28, 2002.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. F. Innominato, C. Focan, T. Gorlia, T. Moreau, C. Garufi, J. Waterhouse, S. Giacchetti, B. Coudert, S. Iacobelli, D. Genet, et al. Circadian Rhythm in Rest and Activity: A Biological Correlate of Quality of Life and a Predictor of Survival in Patients with Metastatic Colorectal Cancer Cancer Res., June 1, 2009; 69(11): 4700 - 4707. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ozturk, J. H. Lee, S. Gaddameedhi, and A. Sancar Loss of cryptochrome reduces cancer risk in p53 mutant mice PNAS, February 24, 2009; 106(8): 2841 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Hoffman, T. Zheng, Y. Ba, and Y. Zhu The Circadian Gene NPAS2, a Putative Tumor Suppressor, Is Involved in DNA Damage Response Mol. Cancer Res., September 1, 2008; 6(9): 1461 - 1468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Spiegel Losing Sleep Over Cancer J. Clin. Oncol., May 20, 2008; 26(15): 2431 - 2432. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Grechez-Cassiau, B. Rayet, F. Guillaumond, M. Teboul, and F. Delaunay The Circadian Clock Component BMAL1 Is a Critical Regulator of p21WAF1/CIP1 Expression and Hepatocyte Proliferation J. Biol. Chem., February 22, 2008; 283(8): 4535 - 4542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Hastings, J. S O'Neill, and E. S Maywood Circadian clocks: regulators of endocrine and metabolic rhythms J. Endocrinol., November 1, 2007; 195(2): 187 - 198. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Fouladiun, U. Korner, L. Gunnebo, P. Sixt-Ammilon, I. Bosaeus, and K. Lundholm Daily Physical-Rest Activities in Relation to Nutritional State, Metabolism, and Quality of Life in Cancer Patients with Progressive Cachexia Clin. Cancer Res., November 1, 2007; 13(21): 6379 - 6385. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Krugluger, A. Brandstaetter, E. Kallay, J. Schueller, E. Krexner, S. Kriwanek, E. Bonner, and H. S. Cross Regulation of Genes of the Circadian Clock in Human Colon Cancer: Reduced Period-1 and Dihydropyrimidine Dehydrogenase Transcription Correlates in High-Grade Tumors Cancer Res., August 15, 2007; 67(16): 7917 - 7922. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Levi, E. Filipski, I. Iurisci, X. M. Li, and P. Innominato Cross-talks between Circadian Timing System and Cell Division Cycle Determine Cancer Biology and Therapeutics Cold Spring Harb Symp Quant Biol, January 1, 2007; 72(0): 465 - 475. [Abstract] [PDF]
|
|
|
|
|
|
I. Iurisci, E. Filipski, J. Reinhardt, S. Bach, A. Gianella-Borradori, S. Iacobelli, L. Meijer, and F. Levi Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor. Cancer Res., November 15, 2006; 66(22): 10720 - 10728. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Gholam, S. Giacchetti, C. Brezault-Bonnet, M. Bouchahda, D. Hauteville, R. Adam, B. Ducot, O. Ghemard, F. Kustlinger, C. Jasmin, et al. Chronomodulated Irinotecan, Oxaliplatin, and Leucovorin-Modulated 5-Fluorouracil as Ambulatory Salvage Therapy in Patients with Irinotecan- and Oxaliplatin-Resistant Metastatic Colorectal Cancer Oncologist, November 1, 2006; 11(10): 1072 - 1080. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Zhu, T. Zheng, R. G. Stevens, Y. Zhang, and P. Boyle Does "Clock" Matter in Prostate Cancer? Cancer Epidemiol. Biomarkers Prev., January 1, 2006; 15(1): 3 - 5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Saul, T. M. Oberyszyn, C. Daugherty, D. Kusewitt, S. Jones, S. Jewell, W. B. Malarkey, A. Lehman, S. Lemeshow, and F. S. Dhabhar Chronic Stress and Susceptibility to Skin Cancer J Natl Cancer Inst, December 7, 2005; 97(23): 1760 - 1767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. D. Aydin Sun Exposure May Confound Physical Activity-Prostate Cancer Association Arch Intern Med, November 28, 2005; 165(21): 2538 - 2539. [Full Text] [PDF]
|
|
|
|
|
|
M. A. Gauger and A. Sancar Cryptochrome, Circadian Cycle, Cell Cycle Checkpoints, and Cancer Cancer Res., August 1, 2005; 65(15): 6828 - 6834. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Filipski, P. F. Innominato, M. Wu, X.-M. Li, S. Iacobelli, L.-J. Xian, and F. Levi Effects of Light and Food Schedules on Liver and Tumor Molecular Clocks in Mice J Natl Cancer Inst, April 6, 2005; 97(7): 507 - 517. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Rich, P. F. Innominato, J. Boerner, M. C. Mormont, S. Iacobelli, B. Baron, C. Jasmin, and F. Levi Elevated Serum Cytokines Correlated with Altered Behavior, Serum Cortisol Rhythm, and Dampened 24-Hour Rest-Activity Patterns in Patients with Metastatic Colorectal Cancer Clin. Cancer Res., March 1, 2005; 11(5): 1757 - 1764. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Zhu, H. N. Brown, Y. Zhang, R. G. Stevens, and T. Zheng Period3 Structural Variation: A Circadian Biomarker Associated with Breast Cancer in Young Women Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 268 - 270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Filipski, F. Delaunay, V. M. King, M.-W. Wu, B. Claustrat, A. Grechez-Cassiau, C. Guettier, M. H. Hastings, and L. Francis Effects of Chronic Jet Lag on Tumor Progression in Mice Cancer Res., November 1, 2004; 64(21): 7879 - 7885. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Filipski, V. M. King, M.-C. Etienne, X. Li, B. Claustrat, T. G. Granda, G. Milano, M. H. Hastings, and F. Levi Persistent twenty-four hour changes in liver and bone marrow despite suprachiasmatic nuclei ablation in mice Am J Physiol Regulatory Integrative Comp Physiol, October 1, 2004; 287(4): R844 - R851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Canaple, T. Kakizawa, and V. Laudet The Days and Nights of Cancer Cells Cancer Res., November 15, 2003; 63(22): 7545 - 7552. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Leloup and A. Goldbeter Toward a detailed computational model for the mammalian circadian clock PNAS, June 10, 2003; 100(12): 7051 - 7056. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. G. Lis, J. F. Grutsch, P. Wood, M. You, I. Rich, and W. J M Hrushesky Circadian Timing in Cancer Treatment: The Biological Foundation for an Integrative Approach Integr Cancer Ther, June 1, 2003; 2(2): 105 - 111. [Abstract] [PDF]
|
|
|
|
|
|
M. D. L. Torre and K. I. Block Integrative Tumor Board: Colon Cancer with Liver Metastases Integr Cancer Ther, June 1, 2003; 2(2): 170 - 172. [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||